Market Overview

Sesen Bio's Vicineum US Application For Bladder Cancer Accepted For Review; Shares Spike

  • Under priority review status, the FDA has accepted Sesen Bio Inc's (NASDAQ: SESN) marketing application for review seeking approval for Vicineum for the treatment of high-risk, BCG-unresponsive non-muscle invasive bladder cancer.
  • Additionally, the FDA stated that it is not currently planning to hold an advisory committee meeting to discuss the application.
  • The agency's target action date is August 18.
  • Vicineum is a locally administered fusion protein that targets epithelial cell adhesion molecule antigens on tumor cells' surface to deliver a potent protein payload, Pseudomonas Exotoxin A. 
  • Price Action: SESN gained 23.2% at $3.45 during premarket trading on the last check Tuesday.

Related Articles (SESN)

View Comments and Join the Discussion!

Posted-In: bladder cancerBiotech News Penny Stocks Small Cap FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at